Christopher R. Vakoc
Found that leukaemias depend on the chromatin reader BRD4, launching BET inhibitors, and mapped transcriptional addictions in sarcoma.
Identified BRD4 as a therapeutic target in AML via RNAi screening and developed CRISPR domain-scanning to find druggable protein domains; studies Ewing and rhabdomyosarcoma dependencies.
| Title | Journal | Year |
|---|---|---|
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Nature | 2011 |
Pages like this
not linked directly; found by shared links- TechnologyEpigenetic editing (durable gene silencing)
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), CRISPR functional genomics.
- IdeaSwitch off an undruggable oncogene permanently with epigenetic editing
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), CRISPR functional genomics.
- PersonTodd R. Golub
- ProductEnasidenib
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- PersonStephen B. Baylin
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- ProductTretinoin (all-trans retinoic acid, ATRA)
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- ProductArsenic trioxide
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- IdeaAn open organoid bank for cancers too rare to have models
Shares Cold Spring Harbor Laboratory, Sarcomas (soft tissue, bone, GIST).